SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This ...
Allelica Collaborates with Invitae to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer
Allelica and Invitae (NVTA) aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the life-saving integration of genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback